Category Archives: add

Human cytomegalovirus (HCMV) neutralizing antibodies (NAb)

Human cytomegalovirus (HCMV) neutralizing antibodies (NAb) Human cytomegalovirus (HCMV) causes life-threatening illness in immunosuppressed patients. HCMV envelope proteins viz. glycoprotein B (gB), gH, gL, gO and UL128/UL130/UL131A are essential for the fusion of virus with the host plasma membranes to enter into the host cell. The gB protein is the direct mediator of cell fusion […]

Virus like particles (VLP) Expression platforms

Structure of capsid proteins is important to stimulate the immune response and it is depended on the post translational modification of different expression systems. The various expression systems such as prokaryotic (bacteria, yeast) or eukaryotic (baculovirus/insect cell, mammalian cell and plant) have been used to produce the VLP.  In addition, cell-free expression systems have also […]

Influenza virus neutralizing antibodies (NAb)

Influenza virus neutralizing Influenza is a transmissible acute respiratory disease caused by the influenza virus. The glycoprotein, hemagglutinin (HA) of influenza virus plays an important role during the viral infection. It helps the virus to bind the cell surface receptors, and transfer the genetic materials into the host cytoplasm through fusion. The neutralizing antibodies against […]

Zaire Ebola virus neutralizing antibodies (NAb)

Zaire Ebola virus neutralizing antibodies (NAb) Zaire Ebola virus belongs to the family Filoviridae, which are highly lethal and it outbreaks since emerging in 1967, including a sustained epidemic in West Africa from 2013 to 2015. Zaire Ebolavirus (EBOV) glycoprotein (GP) is now the key target of antibodies. GP is composed of ectodomain GP1 and a trans-membrane […]

Respiratory syncytial virus (RSV) neutralizing antibodies (NAb)

Respiratory syncytial virus (RSV) neutralizing antibodies (NAb) Respiratory syncytial virus (RSV) enters into the host cells through the type I fusion (F) glycoprotein. Neutralizing monoclonal antibodies, such as Suptavumab, Palivizumab, Nirsevimab, Motavizumab, Gontivimab, and felvizumab target the major antigenic sites on the RSV F glycoprotein and neutralize the entry process. FDA approved neutralizing antibodies (NAb) […]

Rabies virus neutralizing antibodies (NAb)

Rabies virus neutralizing antibodies (NAb) Rabies virus is the causative agent of the rabies. The Rabies Virus Spike Glycoproteins are the important protein responsible for the virus entry and the major target of neutralizing antibodies. GeneMedi offers the Rabies Virus Spike Glycoprotein G, Rabies Virus Surface Glycoprotein 4 (gp4) Epitope 1, Rabies Virus Strain ERA GP Ectodomain Epitope […]

Hepatitis B virus (HBV) neutralizing antibodies (NAb)

Hepatitis B virus (HBV) neutralizing antibodies (NAb) Hepatitis B virus (HBV) surface antigen (HBsAg) is considered to be the most important target for the diagnosis and immune prophylaxis of HBV infection. HBsAg-specific monoclonal antibodies (MAbs) are extensively used for studying the complex structure of the HBsAg, mapping the neutralizing epitopes and development of HBV diagnostic […]

Antibody-drug conjugate (ADC) in clinical application (Approved/BLA, phaseI/II/III)

FDA approved Antibody-drug conjugate (ADC) for clinical use Clinically, most of the ADC drugs approved by FDA are IgG1, and the targets are CD33, CD22, HER2 and so on. The most common payload is MMAE, also contains calicheamicin, DM1. ADC drugs are mainly used in the field of antitumor, which is one of the hot […]

What is antibody-drug conjugate (ADC)?

The structure of antibody-drug conjugate (ADC) ADC consists of antibodies and payload, linker connects antibodies and small molecule drugs. After ADC drugs enter the blood, its antibody part will recognize and bind to the surface antigen of target cells. Theninternalizing ADC antigen complex into cells through endocytosis, the complex will be degraded by lysosomes and […]

Product data of ADC

Product List Case study: Product data of Antibody-drug conjugate (ADC) Antibody Payload QC Ab-001 VCMMAE SDS-PAGE(reducing and non-reducing) Human IgG1 Control DAR Ab-002 Cytotoxity assay First, we used a higher dose of reducing agent (TCEP) and small toxic molecule (vcmmae) to ensure the success of coupling. SDS-PAGE (reducing DTT & non reducing DTT) results showed […]